Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
- Resource Type
- Article
- Source
- In
European Journal of Medicinal Chemistry 15 December 2022 244 - Subject
- Language
- ISSN
- 0223-5234